scholarly journals Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

2016 ◽  
Vol 17 (12) ◽  
pp. 1672-1682 ◽  
Author(s):  
Daniel R Gomez ◽  
George R Blumenschein ◽  
J Jack Lee ◽  
Mike Hernandez ◽  
Rong Ye ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Maintenance Therapy ◽  
Small Cell Lung Cancer ◽  
Systemic Therapy ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
Phase 2 Study ◽  
Randomised Controlled

Abstract 4606: Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)

2012 ◽  
Author(s):  
Alice T. Shaw ◽  
Doru Ghizdavescu ◽  
Minish Jain ◽  
Constantin Volovat ◽  
Deepa Subramaniam ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2

A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. TPS9084-TPS9084
Author(s):  
Amy Lauren Cummings ◽  
David Dae-Young Kim ◽  
Lee S. Rosen ◽  
Edward B. Garon ◽  
Zev A. Wainberg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Maintenance Therapy ◽  
Small Cell Lung Cancer ◽  
Dose Level ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
Extensive Stage ◽  
Phase 1B

TPS9084 Background: Maintenance therapy is a promising therapeutic approach for extensive-stage small cell lung cancer (ES-SCLC), especially in light of IMpower 133 (Horn NEJM 2018). SCLC models of poly (ADP-ribose) polymerase (PARP) protein 1 and 2 inhibition suggested synergy with temozolomide (TMZ) (Wainberg AACR 2016). Combining PARP inhibition and TMZ with atezolizumab after first-line therapy for ES-SCLC may improve disease control. Methods: This is a phase 1b/2, randomized, open-label study of TMZ plus niraparib, a PARP inhibitor, with atezolizumab versus atezolizumab as maintenance therapy in adult patients with ES-SCLC after completion of platinum-based first-line chemotherapy. The primary outcome for phase 1b is the RP2D of TMZ in combination with niraparib, and for phase 2, progression-free survival (PFS). Secondary endpoints include safety, objective response rate, and overall survival. Exploratory endpoints include adverse events and patient-reported outcomes, including health-related quality of life. Phase 1b participants are required to have an advanced and incurable solid malignancy. Part one of phase 1b includes an accelerated lead-in of 12 participants treated in cohorts of 6 with an initial dose level of niraparib 200 mg po daily in 28-day cycles and low-dose TMZ 40 mg po daily on days 1-5 of each cycle. Part two includes a safety lead-in of 6 patients receiving standard-of-care atezolizumab, to which R2PD niraparib and TMZ will be added. For phase 2, participants are required to have ES-SCLC with a complete response or partial response per RECIST 1.1 following 4 to 6 cycles of platinum-based chemotherapy and ability to proceed to randomization within 7 weeks after day 1 of the last cycle of prior chemotherapy. Prophylactic WBRT is allowed prior to study. 52 participants will be stratified by a history of brain metastases and randomized 1:1 to atezolizumab with or without RP2D niraparib plus TMZ. There will be no cross-over between arms. To date, cohort 1 had two DLTs. Enrollment to dose level -1 and an intermediate dose have been completed without a DLT. The atezolizumab safety lead-in begins enrollment in March 2020. Clinical trial information: NCT03830918.

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

2013 ◽  
Vol 49 (15) ◽  
pp. 3111-3121 ◽  
Author(s):  
Dae Ho Lee ◽  
Jung Shin Lee ◽  
Sang-We Kim ◽  
José Rodrigues-Pereira ◽  
Baohui Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Study ◽  
Never Smokers ◽  
Randomised Controlled

Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study

Lung Cancer ◽  
2014 ◽  
Vol 86 (1) ◽  
pp. 47-53
Author(s):  
Armando Santoro ◽  
Gunnar N. Hillerdal ◽  
Gert Hoeffken ◽  
Adolfo Favaretto ◽  
Ramon Perez Carrion ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
Phase 2 Study ◽  
First Line Treatment

scholarly journals A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)

2016 ◽  
Vol 27 ◽  
pp. vi441 ◽  
Author(s):  
M. Johnson ◽  
V. Wacheck ◽  
M. Hussein ◽  
M. McCleod ◽  
D. Daniel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
Phase 2 Study ◽  
Line Chemotherapy

Multicenter Phase 2 Study of Interleukin-2 and 13-Cis Retinoic Acid as Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer

2006 ◽  
Vol 29 (1) ◽  
pp. 87-94 ◽  
Author(s):  
Francesco Recchia ◽  
Gaetano Saggio ◽  
Antonio Nuzzo ◽  
Edoardo Biondi ◽  
Anna Di Blasio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retinoic Acid ◽  
Maintenance Therapy ◽  
Small Cell Lung Cancer ◽  
Interleukin 2 ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Multicenter Phase ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document